Marginal Zone Lymphoma clinical trials

Explore recruiting marginal zone lymphoma clinical trials.

Recruiting marginal zone lymphoma studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Marginal Zone Lymphoma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Phase II trial of acalabrutinib in combination with tafasitamab in patients with previously treated marginal zone lymphomas (MZL)

Italy, Austria

Therapeutic exploratory (Phase II) EU CTIS Study details

Copanlisib and Rituximab in Marginal Zone Lymphoma Patients - A MULTICENTER OPEN LABEL SINGLE-ARM PHASE II STUDY (COUP-1)

Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

Epcoritamab in Relapsed/Refractory Marginalzone Lymphoma - A MULTICENTER OPEN LABEL SINGLE-ARM PHASE II STUDY (EPOS-1)

Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

A PHASE 2, OPEN-LABEL, SINGLE-ARM, MULTICOHORT, MULTICENTER TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF JCAR017 IN ADULT SUBJECTS WITH RELAPSED OR REFRACTORY INDOLENT B-CELL NON-HODGKIN LYMPHOMA (NHL) (Transcend FL)

Sweden, France, Spain, Austria, Germany, Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

A pivotal phase 3 clinical trial to assess the diagnostic performance and safety of [68Ga]Ga-PentixaFor ([68Ga]Ga-PTF), a positron emission tomography (PET) imaging agent, versus [18F]FDG PET/CT imaging, for staging of patients with confirmed marginal zone lymphoma (MZL) exemplary for CXCR4-positive malignant lymphomas: a prospective, international, multi-center, comparative, randomized, cross-over, open-label lymphoma diagnostic trial (LYMFOR).

Germany, Italy, Spain, France, Austria

Therapeutic confirmatory (Phase III) EU CTIS Study details

Obinutuzumab in marginal zone lymphoma - A MULTICENTER OPEN LABEL SINGLE-ARM PHASE II STUDY (OLYMP-1)

Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

Marginal Zone Lymphoma trials by city

Marginal Zone Lymphoma in Toronto Marginal Zone Lymphoma in Vancouver Marginal Zone Lymphoma in Montreal Marginal Zone Lymphoma in Calgary Marginal Zone Lymphoma in Edmonton Marginal Zone Lymphoma in Ottawa Marginal Zone Lymphoma in Winnipeg Marginal Zone Lymphoma in Quebec City Marginal Zone Lymphoma in Hamilton Marginal Zone Lymphoma in Kitchener Marginal Zone Lymphoma in London Marginal Zone Lymphoma in Halifax Marginal Zone Lymphoma in New York Marginal Zone Lymphoma in Los Angeles Marginal Zone Lymphoma in Chicago Marginal Zone Lymphoma in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease